Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DY2EJ1
|
|||
Drug Name |
ATA2431
|
|||
Drug Type |
CAR T Cell Therapy
|
|||
Indication | B-cell lymphoma [ICD-11: 2A86; ICD-10: C85.1; ICD-9: 202.8] | Preclinical | [1] | |
Company |
Atara Biotherapeutics
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | B-cell receptor CD22 (CD22) | Target Info | . | [1] |
B-lymphocyte surface antigen B4 (CD19) | Target Info | . | [1] | |
Leukocyte surface antigen Leu-16 (CD20) | Target Info | . | [1] | |
KEGG Pathway | Cell adhesion molecules (CAMs) | |||
Hematopoietic cell lineage | ||||
B cell receptor signaling pathway | ||||
PI3K-Akt signaling pathway | ||||
Epstein-Barr virus infection | ||||
Primary immunodeficiency | ||||
NetPath Pathway | IL-7 Signaling Pathway | |||
Panther Pathway | B cell activation | |||
Pathway Interaction Database | BCR signaling pathway | |||
Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
PIP3 activates AKT signaling | ||||
Constitutive Signaling by Aberrant PI3K in Cancer | ||||
WikiPathways | B Cell Receptor Signaling Pathway | |||
Human Complement System | ||||
Signaling by the B Cell Receptor (BCR) | ||||
PIP3 activates AKT signaling | ||||
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of Atara Biotherapeutics. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.